How many prescriptions did Lilly's Foundayo receive in its fourth week on the U.S. market, and how does that compare to expectations?

Lilly's Foundayo received 7,335 prescriptions in its fourth week in the U.S., a figure analysts described as 'modest uptake' compared to Novo Nordisk's Wegovy. To meet consensus second-quarter sales expectations of $160 million, Foundayo would need approximately 22,000 prescriptions per week — meaning the current volume falls significantly short of that target.

What do Lilly's reported prescriber and patient numbers reveal about Foundayo's early adoption beyond prescription counts?

Lilly reported that Foundayo has over 8,000 prescribers, with one-third having no prior experience prescribing oral GLP-1 medications, and that more than 20,000 patients have been treated — indicating broader clinical engagement and real-world use beyond the 7,335 retail-plus-sampled telehealth/LillyDirect prescriptions tracked by IQVIA in week four.

Lilly's Obesity Pill Tops 7,000 Prescriptions in Fourth Week, Signals Modest Uptake

May 8, 2026

Eli Lilly's new oral weight-loss drug Foundayo recorded 7,335 prescriptions in its fourth week, trailing rival Wegovy but showing early traction. Analysts suggest investors are looking past initial metrics as the drug expands access via telehealth and retail channels.

reuters

2026-01-13

Jan. 13 Business Watch: Plants Close in Brazil and the UK; Lilly to Pay $1.2 Billion for Ventyx

2026-04-17

Lilly's obesity pill Foundayo gets 1,390 prescriptions in debut week

2026-04-19

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

2026-04-24

Eli Lilly's Obesity Pill Records Modest Second Week as Battle with Novo Nordisk Intensifies

2026-04-30

S&P 500, Nasdaq On Course for Best Month Since 2020 Despite Middle East Risks